All In Biotech

Drug Trial Radar · NCT05253053

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Apr 13, 2022

Primary completion

Aug 31, 2024

Study completion Aug 31, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and TNBC).

Conditions

  • Advanced Solid Tumor
  • Cholangiocarcinoma
  • Biliary Tract Cancer
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • Small-cell Lung Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Gastric Cancer
  • Gallbladder Cancer

Interventions

  • TT-00420Drug

    TT-00420 tablet will be administered orally once daily per protocol defined schedule.

  • Combination Product: AtezolizumabDrug

    Atezolizumab would be administered via infusion on Day 1 of 21-day cycle

  • Combination Product: Nab-PaclitaxelDrug

    Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 30 days from the last dose
  2. Dose limiting toxicity (DLT)Time frame: Up to 21 days from the first dose

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Fudan Univisity Shanghai Cancer Center

    Shanghai, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.